StemRIM Earnings beat, Revenue Inline In Q4
- Investing.com
Metrics to compare | 4599 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4599PeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.2x | −5.3x | −0.2x | |
PEG Ratio | −0.85 | −0.20 | 0.00 | |
Price/Book | 1.4x | 3.0x | 2.6x | |
Price / LTM Sales | - | 12.8x | 2.7x | |
Upside (Analyst Target) | - | 135.0% | 69.6% | |
Fair Value Upside | Unlock | 15.0% | 11.7% | Unlock |
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, acute ischemic stroke, cerebral infarction, myocardial infarction/cardiomyopathy, chronic liver disease, and knee osteoarthritis. It also develops TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a gene therapy for the treatment of epidermolysis bullosa. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.